Fortress Biotech Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FBIO Nasdaq 2836 https://www.fortressbiotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fortress Biotech Inc

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference - Sep 21st, 2023 12:30 pm
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference - Sep 7th, 2023 12:30 pm
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences - Sep 7th, 2023 12:15 pm
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference - Sep 6th, 2023 12:30 pm
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations - Sep 6th, 2023 12:00 pm
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference - Sep 5th, 2023 12:30 pm
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy - Aug 16th, 2023 12:00 pm
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights - Aug 14th, 2023 8:15 pm
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights - Aug 14th, 2023 8:05 pm
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights - Aug 14th, 2023 8:01 pm
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights - Aug 10th, 2023 8:15 pm
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights - Aug 8th, 2023 8:01 pm
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023 - Aug 3rd, 2023 12:30 pm
Mustang Bio to Participate in Two August 2023 Investor Conferences - Aug 3rd, 2023 12:00 pm
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 - Aug 2nd, 2023 8:01 pm
Insiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77m - Aug 1st, 2023 6:54 pm
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study - Aug 1st, 2023 12:30 pm
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences - Jul 31st, 2023 12:30 pm
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market - Jul 31st, 2023 12:00 pm
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - Jul 27th, 2023 12:30 pm